Literature DB >> 143813

Combination chemotherapy with 1-methyl-1-nitrosourea (MNU) and cyclophosphamide in solid tumors.

K Kolarić.   

Abstract

Twenty-four patients with far advanced malignant tumors, resistent to established chemotherapy,, were treated with the combination of MNU and Cyclophosphamide. The drugs were administered in six-day cycles sequentially. MNU in doses of 4 mg/kg body weight and Cyclophosphamide in doses of 8 mg/kg body weight were given. Results of treatment showed response (greater than 50% tumor regression) in 10 (42%) of the 24 treated patients. Seven remissions were complete and three partial. Patients with Hodgkin's disease, malignant melanoma and breast cancer responded to this combination chemotherapy. Objective remissions were obtained also in five of thirteen patients with primary or metastatic brain tumors and in five of nine patients with pulmonary metastases. Nausea and vomiting were the main toxic effects, especially after injections of MNU. Myelosuppression was noted in about 50% of treated patients. Since this combination of cytostatics showed significant antitumor activity, further investigations are necessary on a larger number of patients and in other types of malignant tumors.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 143813     DOI: 10.1007/bf00283785

Source DB:  PubMed          Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol        ISSN: 0084-5353


  15 in total

1.  Activity of cyclophosphamide and 1-methylnitrosourea on Ehrlich carcinoma transplanted in different sites. Correlation between drug level and tumor inhibition.

Authors:  A Bossi; T Colombo; M G Donelli; S Garattini
Journal:  Biochem Pharmacol       Date:  1975-01-01       Impact factor: 5.858

2.  ANTILEUKEMIC ACTIVITY OF HYDROXYUREA (NSC-32065) AND OTHER UREA DERIVATIVES.

Authors:  A GOLDIN; J M VENDITTI; J A MEAD; J P GLYNN
Journal:  Cancer Chemother Rep       Date:  1964-08

Review 3.  Combined modality therapy for intracranial tumors.

Authors:  H J Bloom
Journal:  Cancer       Date:  1975-01       Impact factor: 6.860

4.  Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).

Authors:  J C Marsh; R C DeConti; S P Hubbard
Journal:  Cancer Chemother Rep       Date:  1971-12

5.  Experimental and clinical studies of the antitumor activity of 1-methyl-1-nitrosourea (NSC-23909).

Authors:  N M Emanuel; E M Vermel; L A Ostrovskaya; N P Korman
Journal:  Cancer Chemother Rep       Date:  1974 Mar-Apr

6.  [Use of N-nitroso methylurea in lung cancer].

Authors:  N P Korman; E M Vermel'; B V Milonov; R S Orlova
Journal:  Vopr Onkol       Date:  1971

7.  Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962.

Authors:  V T De Vita; P P Carbone; A H Owens; G L Gold; M J Krant; J Edmonson
Journal:  Cancer Res       Date:  1965-12       Impact factor: 12.701

8.  [Experimental brain tumors in rabbits following injection of methylnitrosourea].

Authors:  W Jänisch; D Schreiber
Journal:  Naturwissenschaften       Date:  1967-04

9.  A phase II study of methyl CCNU in the treatment of solid tumors and lymphomas: a Southwest Oncology Group study.

Authors:  B L Tranum; A Haut; S Rivkin; E Weber; J M Quagliana; M Shaw; W G Tucker; F E Smith; M Samson; J Gottlieb
Journal:  Cancer       Date:  1975-04       Impact factor: 6.860

10.  Chemotherapy of primary malignant brain tumors in children.

Authors:  W R Shapiro
Journal:  Cancer       Date:  1975-03       Impact factor: 6.860

View more
  4 in total

Review 1.  N-Methyl-N-nitrosourea as a mammary carcinogenic agent.

Authors:  Ana I Faustino-Rocha; Rita Ferreira; Paula A Oliveira; Adelina Gama; Mário Ginja
Journal:  Tumour Biol       Date:  2015-09-19

2.  The effects of 1-methyl-1-nitrosourea on the survival pattern of cycling and noncycling HeLa cells.

Authors:  J Ban; B Brdar; J Sorić
Journal:  J Cancer Res Clin Oncol       Date:  1979-07-27       Impact factor: 4.553

3.  Treatment of metastatic brain tumors with the combination of 1-methyl-1-nitrosourea (MNU) and cyclophosphamide.

Authors:  K Kolarić; A Roth
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

Review 4.  Chemical carcinogenesis studies in nonhuman primates.

Authors:  Shozo Takayama; Unnur P Thorgeirsson; Richard H Adamson
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2008       Impact factor: 3.493

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.